
Autosomal Dominant Hypocalcemia: Genetic Insights into a Silent Disruptor
Genetic testing revolutionizes Autosomal Dominant Hypocalcemia diagnosis, enhancing accuracy, personalized care, and family planning, uncovering a silent disruptor.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

Genetic testing revolutionizes Autosomal Dominant Hypocalcemia diagnosis, enhancing accuracy, personalized care, and family planning, uncovering a silent disruptor.

Explore how genetic testing identifies PAPSS2 mutations in autosomal recessive brachyolmia, aiding early diagnosis, family planning, and personalized treatment strategies.

Genetic testing enhances early diagnosis and management of autosomal recessive distal renal tubular acidosis, focusing on ATP6V1B1 gene mutations and personalized care.

Genetic testing aids early ARMAMC diagnosis, personalized treatments, and family planning by revealing genetic mutations and offering tailored care solutions.

Unlock the potential of genetic testing in diagnosing Autosomal Recessive Spastic Ataxia. Early detection and personalized care improve outcomes for affected families.

AXIN2-related AFAP increases colorectal cancer risk. Genetic testing identifies gene mutations for early detection, personalized care, and informed family planning.

Explore how genetic testing aids in diagnosing Brain Dopamine-Serotonin Vesicular Transport Disease, offering early detection, personalized treatment, and family planning insights.

Unlock insights into Castleman-Kojima disease with genetic testing. Enhance diagnosis, personalize treatment, and aid in early detection to improve patient outcomes.